MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2017

The quarter in brief Significant events during the first quarter · The osteoarthritis trial evaluating MIV-711 received the go-ahead to continue without any modifications after a positive fourth review of safety data. · Christine Lind has been appointed as the new CEO of Medivir, effective as of 1 April 2017. · Medivir’s Extraordinary General Meeting, held in February, resolved on a voluntary redemption programme comprising a reduction in the share capital for repayment to the shareholders. Total cash proceeds of approximately SEK 857.5 million were distributed. · An